Table 4 Exploratory analyses of total symptom scores, ANCOVA-adjusted means

TSS_{2–4, ex 1 pt}

 I-C

97

5.67 (0.24)

−0.72 (0.34)

(−1.40, −0.05)

0.0364

 Placebo

97

6.39 (0.24)

TSS_1-4

 I-C

98

6.02 (0.21)

−0.60 (0.30)

(−1.19, −0.00)

0.0495

 Placebo

97

6.62 (0.21)

TSS_{1–4, rel}

 I-C

98

−0.08 (0.05)

−0.13 (0.06)

(−0.25, −0.01)

0.0421

 Placebo

97

0.05 (0.05)

Subset analyses

TSS_2–4, virus positive patients

 I-C

53

5.87 (0.34)

−0.80 (0.48)

(−1.75, 0.15)

0.0986

 Placebo

54

6.67 (0.34)

TSS_2–4, HRV/HEV positive patients

 I-C

27

6.08 (0.46)

−0.36 (0.65)

(−1.66, 0.94)

0.5820

 Placebo

28

6.44 (0.46)